[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-failure-and-preserved-ejection-fraction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-failure-and-preserved-ejection-fraction":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,57,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100641477","ehealth-lifestyle-intervention-to-enhance-outcomes-in-hfpef-100641477",false,"NCT07661732","eHealth Lifestyle Intervention To Enhance Outcomes in HFpEF","Randomized Trial Of A Digital Lifestyle Education Strategy In Patients With Heart Failure And Overweight Or Obesity: The ELITE-HFpEF Study","ELITE-HFpEF","Inclusion Criteria:\n\n* Age over 18 years\n* Body mass index (BMI) over 27 kg\u002Fm²\n* Symptoms consistent with heart failure\n* Left ventricular ejection fraction (LVEF) of 50% or higher\n* Elevated NT-proBNP according to the European Society of Cardiology age-adjusted rule-in thresholds: 125 pg\u002FmL or higher if under 50 years, 250 pg\u002FmL or higher if 50 to 75 years, and 500 pg\u002FmL or higher if 75 years or older\n* Echocardiographic abnormalities: left ventricular hypertrophy, left atrial enlargement, or diastolic dysfunction\n\nExclusion Criteria:\n\n* Body mass index (BMI) over 40 kg\u002Fm²\n* Life expectancy of less than 1 year\n* Chronic kidney disease on renal replacement therapy\n* Moderate or greater valvular heart disease\n* Inability to exercise","ALL","18 Years",{"count":20,"type":21},52,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if a digital lifestyle education program improves exercise capacity in adults who have heart failure with preserved ejection fraction (HFpEF) and overweight or obesity. HFpEF is a type of heart failure in which the heart muscle is stiff and does not relax well, even though its pumping strength looks normal. The main questions it aims to answer are:\n\n* Does the program improve how much oxygen participants can use during exercise, a measure of fitness, after 6 months?\n* Does the program improve participants' quality of life and help them lose weight?\n\nResearchers will compare a group that uses the digital program plus usual care to a group that receives usual care alone. This will show whether the program adds a benefit.\n\nParticipants will:\n\n* Be placed by chance into one of the two groups\n* Use a study website with short videos on exercise, healthy eating, and managing stress (program group), with new content every week for 6 months\n* Have exercise tests, an ultrasound scan of the heart, blood tests, and complete a quality-of-life questionnaire at the start and after 6 months\n\nBoth groups will keep taking their usual heart failure medicines.",[27,28,29],"Heart Failure and Preserved Ejection Fraction","Obesity & Overweight","Heart Failure",[31,32,33,34,35,36,37,38,39,40,41,42,43],"HFpEF","obesity","overweight","digital health","eHealth","mHealth","telemedicine","web-based intervention","lifestyle intervention","cardiac rehabilitation","Mediterranean diet","cardiopulmonary exercise testing","quality of life","NOT_YET_RECRUITING","2026-06-16",{"date":47,"type":48},"2026-06-22","ACTUAL",{"date":50,"type":21},"2026-09-01",{"date":52,"type":21},"2029-06-30",{"name":54,"class":55},"Maimónides Biomedical Research Institute of Córdoba","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":68,"conditions":69,"keywords":75,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100634736","phase-3-selenium-intervention-registry-randomized-trial-in-heart-failure-100634736","NCT07543562","Selenium Intervention Registry Randomized Trial in Heart Failure","SIRI-HF","Inclusion Criteria:\n\nTo be considered for inclusion in this study, patients must meet all of the following eligibility requirements:\n\n* 18 years of age\n* primary discharge diagnosis of HF coded as ICD-10: I50, as recorded in The SwedeHF registry\n* be able to provide documented informed consent by signing and dating the designated consent form.\n\nExclusion Criteria:\n\n* Not suitable in the opinion of the Investigator (for example due to severe or terminal comorbidity with poor prognosis, or characteristics, pregnancy etc.) that may interfere with adherence to trial protocol",{"count":65,"type":21},4326,[67],"PHASE3","Heart failure is a serious condition in which the heart is unable to pump blood effectively, and it remains a leading cause of hospitalization and death worldwide despite advances in treatment.\n\nSelenium is an essential micronutrient that plays an important role in cellular energy production, antioxidant defense, and overall cardiovascular function. Low selenium levels are common among patients with heart failure in Northern Europe, and observational studies have shown that selenium deficiency is associated with an increased risk of hospitalization and death. In cases of severe deficiency, such as in Keshan disease, heart dysfunction can be reversed with selenium supplementation, suggesting a potential causal relationship.\n\nHowever, it is not yet known whether selenium supplementation can improve clinical outcomes in patients with heart failure when added to standard medical therapy.\n\nThe SIRI-HF trial is a randomized, placebo-controlled study designed to evaluate whether daily supplementation with 200 micrograms of selenium, in addition to guideline-directed medical therapy, improves outcomes in patients with heart failure.\n\nThe primary endpoint is a composite of recurrent heart failure hospitalizations and cardiovascular death. Secondary endpoints include all-cause mortality, changes in symptoms and functional status, and safety outcomes.\n\nThis study will include patients from Sweden and Norway and aims to determine whether correcting selenium deficiency can improve prognosis in heart failure.",[29,70,71,27,72,73,74],"Heart Failure and Reduced Ejection Fraction","Heart Failure and Mildly Reduced Ejection Fraction","Selenium Supplementation","Selenium","Cognitive Functioning",[76,77,78,62],"heart failure","selenium","RRCT","RECRUITING","2026-04-15",{"date":82,"type":48},"2026-04-22",{"date":84,"type":48},"2026-04-01",{"date":86,"type":21},"2031-03",{"name":88,"class":55},"Skane University Hospital",11,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":98,"sex":17,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":102,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":56},"100634444","obese-hfpef-towards-preventing-obesity-related-hfpef-100634444","NCT07539766","OBESE-HFpEF: Towards Preventing Obesity Related HFpEF","OBESE-HFpEF: Prevalence and Mediators of Heart Failure (Preserved Ejection Fraction) in the Dutch Obesity Clinic South - Towards Preventing Obesity Related HFpEF''","OBESE-HFpEF","Inclusion Criteria:\n\n* Age ≥ 35 years\n* Eligible for surgical treatment for obesity, according to the Dutch guideline, i.e. a BMI ≥ 40 kg\u002Fm2 or a BMI ≥ 35 kg\u002Fm2 with one or more comorbidities associated with obesity. (23)\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* A BMI \\>60 kg\u002Fm2\n* Inability of undergoing metabolic bariatric surgery safely.\n* Inability to undergo the study measurement\u002Ftests.\n* Not proficient in the Dutch language\n* A medical history of a reduced LVEF at any time, history of severe cardiac valve defects or severe congenital cardiac defects.\n* A medical history of previous metabolic bariatric surgery.",true,"35 Years",{"count":101,"type":21},250,"2 Years","OBSERVATIONAL","Obesity, severe overweight, is a growing problem worldwide and increases the risk of heart failure, especially a type called heart failure with preserved ejection fraction (HFpEF).\n\nIn HFpEF, the heart becomes stiffer. This makes it harder for the heart to fill with blood, which can lead to shortness of breath during physical activity.\n\nIn the Netherlands, 15% of the population has obesity. In South Limburg, this is even higher at 19%. Among people with HFpEF, obesity is much more common: about 50% of these patients have obesity.\n\nLife expectancy in people with HFpEF is poor, and current treatment mainly focuses on reducing symptoms. Early recognition and treatment of risk factors, such as obesity, are therefore very important.\n\nThis study includes about 250 people with obesity. Using a heart ultrasound and tests of blood and fat tissue, we will look for early signs of HFpEF and study the effects of weight loss. The measurements will be repeated after 1 and 2 years.\n\nThe goal of this study is to better understand how obesity contributes to HFpEF and how weight loss affects the heart. This research may help improve future treatments for patients with HFpEF.",[27,106,29],"Obesity (Disorder)",[108,109,110,111],"Obesity","Heart Failure with preserved ejection fraction","Metabolic Bariatric Surgery","Prospective","2026-04-13",{"date":114,"type":48},"2026-04-20",{"date":116,"type":48},"2025-01-01",{"date":118,"type":21},"2029-01-01",{"name":120,"class":55},"Zuyderland Medisch Centrum"]